Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.19  Related to the article below (Last Update: 8/4/2008)

Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
APAC Customer Services Announces Second Quarter 2008 Results MarketWatch
all 70 news articles »  APAC
Ubuntu Security Notice - devhelp, epiphany-browser, midbrowser ...
Help Net Security, Croatia -
The problem can be corrected by upgrading your system to the following package versions: Ubuntu 8.04 LTS: devhelp 0.19-1ubuntu1.8.04.3 epiphany-gecko ...
Altra Holdings Announces Record Financial Results for the Second ...
MarketWatch -
Also, the company has posted slides on its web site at http://www.altramotion.com in the Investor Relations Section in the Events & Presentations tab to ...AIMC
FMC Corporation Announces Second Quarter 2008 Results
MarketWatch - Jul 29, 2008
This event will be available live and as a replay on the web at http://www.fmc.com. Prior to the conference call, the Company will also provide supplemental ...FMC

Earthtimes (press release)
McAfee, Inc. Reports 26 Percent Growth on Record Revenue of $397 ...
MarketWatch - Jul 31, 2008
McAfee Secure Search Service, delivering one of the safest online search experiences for consumers, and McAfee SECURE(TM) for Web Sites, ...
Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased ... Trading Markets (press release)
all 1,236 news articles »  MFE - AMGN - HPQ
Firefox 3 chipping away Safari market share, summer browsing ...
TG Daily - Aug 1, 2008
For instance, on June 1 0.19% of users were browsing the web using an iPhone. Following June 11, when the iPhone 3G was introduced, that share increased to ...
Xantrex(TM) Technology Inc. Reports 2008 Second Quarter
MarketWatch - Jul 29, 2008
Our complete second quarter 2008 Management's Discussion and Analysis and Financial Statements are available on the Xantrex web site at www.xantrex.com. ...TSE:XTX - TPO:5468 - OTC:CMTX

WELT ONLINE
Susquehanna Bancshares, Inc. Announces Second Quarter Results
WELT ONLINE, Germany - Jul 23, 2008
Investors will have the opportunity to listen to the conference call through a live broadcast on Susquehanna?s Web site. The event may be accessed by ...
Columbia Bancorp Releases Second Quarter Financial Results ... FOXBusiness
TriCo Bancshares Announces Quarterly Earnings MarketWatch
Cascade Bancorp (Oregon) Announces Second Quarter 2008 Net Income ... MSN Money
Primenewswire (press release) - MarketWatch
all 1,034 news articles »  SUSQ - FSGI - TCBK
Dominion Announces Second-Quarter 2008 Earnings
Earthtimes (press release), UK - Jul 31, 2008
4) Refer to schedules 2 and 3 for details related to items excluded from operating earnings, or find "GAAP Reconciliation" on Dominion's Web site at ...D
Qualcomm Announces Third Quarter Fiscal 2008 Results
FOXBusiness - Jul 23, 2008
Prior period reconciliations are presented on Qualcomm's Investor Relations web page at www.qualcomm.com. "We are pleased to report another strong quarter ...QCOM
Source: Google News

Web caching and Zipf-like distributions: evidence and implications -
L Breslau, P Cao, L Fan, G Phillips, S Shenker - INFOCOM'99. Eighteenth Annual Joint Conference of the IEEE …, 1999 - ieeexplore.ieee.org
... Questnet NLANR L0.04 -0.08 0.003 -0.04 -0.02 -0.09 DEC UPisa FuNet UCB Questnet
NLANR -0.19 -0.27 0.005 0.002 -0.03 -0.08 the total number of web documents, q ...

Predicting the use of web-based information systems: self-efficacy, enjoyment, learning goal … -
MY Yi, Y Hwang - International Journal of Human-Computer Studies, 2003 - Elsevier
... d. ability to use favorite Web site 0.19 0.78 0.31 0.56 0.12 0.20 0.29 3.
Enjoyment a. have fun using0.11 0.24 0.95 0.46 0.48 0.47 0.07 ...

Measuring web site quality improvements: a case study of the forum on strategic management knowledge … -
SJ Barnes, R Vidgen - Industrial Management & Data Systems, 2003 - emeraldinsight.com
... 1.63 18 Conveys a sense of community 4.35 0.19 1.51 3.67 0.22 1.70 4.59 0.24 ... 0.21
1.66 5.10 0.17 1.32 4.95 0.18 1.37 20 What is your overall view of this Web

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
Page 1. THE WORLD BANK ECONOMIC REVIEW. VOL. 6. NO. 1: 35J-J9J Measuring the
Independence of Central Banks and Its Effect on Policy Outcomes ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle ... Esters
Methyl tetradecanoate (myristate) 0.19 (0.05) 0.55 (0.11)* ...

The detrital food web in a shortgrass prairie -
HW Hunt, DC Coleman, ER Ingham, RE Ingham, ET … - Biology and Fertility of Soils, 1987 - Springer
... HW Hunt et al.: The detrital food web in a shortgrass prairie ... 0.8 0.8 0.00058 0.56
0.19 0.8 0.8 0.0020 0.56 0.10 0.8 1.0 0.0020 0.56 0.10 0.5 0.8 0.021 0.56 ...

User Control and Structural Isomorphism or Disorientation and Cognitive Load?: Learning From the Web … -
WP EVELAND JR, S DUNWOODY - Communication Research, 2001 - crx.sagepub.com
... Web expertise 23.97 1 23.97 4.85 0.19 .03 .026 Cognitive load 43.48 1 43.48 8.80
?0.16 .00 .046 ... Web expertise 22.45 1 22.45 5.60 0.19 .02 .030 ...

[PDF] Removal policies in network caches for world-wide web documents -
S Williams, M Abrams, CR Strandridge, G Abdulla, E … - Computer Communication Review, 1996 - cs.kent.edu
... in networks with workloads like ours could dramat- ically reduce the load on popular
Web servers. ... Video 0.19 18.29 0.35 25.77 0.34 39.15 0.00 0.04 0.04 3.58 ...
-

Regulation of Lake Primary Productivity by Food Web Structure -
SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR
... December 1987 LAKE PRODUCTIVITY AND FOOD WEB STRUCTURE 1869 0.6-- 0.4- 0.2- 0 6-
4- 1984 I ... SE -- 0.47, n = 13) in 1984 to 1.14 x 106/um3/mL (SE = 0.19, n = 13 ...

The development of two tools for measuring the easiness and usefulness of transactional Web sites -
AM Aladwani - European Journal of Information Systems, 2002 - ingentaconnect.com
... Table 5 Factor analysis results for Web site easiness & usefulness?holdout sample ...
Ease of finding the site 0.21 0.03 0.19 0.05 0.21 0.04 0.88 ...

Source: Google Scholar
 
 

Inovio Biomedical Partner Tripep Files Application For Phase I Clinical Study Of Hepatitis C DNA Vaccine

Article Date: 09 Dec 2006 - 4:00am (PST)
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced recently that its partner, Tripep AB of Sweden, has filed an application for a phase I clinical study with the Swedish Medical Products Agency. The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C®, administered using Inovio's MedPulser® DNA Delivery System. This combination is designed to activate a T-cell response capable of clearing hepatitis C virus. Tripep intends to conduct a phase I clinical study in healthy volunteers at the Center for Gastroenterology at Karolinska University Hospital in Sweden beginning in early 2007.

"Our partnership with Tripep has rapidly moved this vaccine from concept to initial clinical evaluation in less than a year," stated Avtar Dhillon, MD, Inovio's president and CEO. "This vaccine trial represents the first study in man of an infectious disease vaccine delivered with electroporation and we are excited about the product's potential."

About Inovio's DNA Delivery Technology

DNA vaccines have the potential to by-pass the numerous problems that plague conventional vaccines. For example, DNA vaccines may be better in stimulating cellular immunity necessary to fight chronic infection or diseases such as cancer. Despite this promise, vaccination using DNA plasmids alone, without enhanced delivery, has not been shown to reach the threshold for clinical benefit.

Article continues below and (thank you)
 
Intramuscular delivery of DNA vaccines using Inovio's proprietary electroporation technology has been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Plasmid-based vaccines induced higher levels of antibodies and T-cell responses when delivered via electroporation, suggesting the potential to provide better protection from infectious diseases such as HIV and hepatitis C.

About Hepatitis C and ChronVac-C

Hepatitis is a disease characterized by inflammation of the liver. Hepatitis C virus (HCV) is a major cause of acute hepatitis. HCV is spread primarily by direct contact with human blood, the major causes worldwide being the use of unscreened blood transfusions and re-use of needles and syringes that have not been adequately sterilized. As many as 70% - 90% of newly infected patients may progress to develop chronic infection (WHO: 2002). Of those with chronic liver disease, 5% - 20% may develop cirrhosis. About 5% of infected persons may die from the consequences of long term infection (due to liver cancer or cirrhosis). Globally, an estimated 170 million people are chronically infected with HCV, which represents a reservoir sufficiently large for HCV to persist, and 3 to 4 million persons are newly infected each year. In the US, while new incidences of HCV have dropped dramatically, an estimated 4.1 million (1.6%) Americans have been infected with HCV, of whom 3.2 million are chronically infected (Centers for Disease Control and Prevention: 2006).

HCV infections in the liver do not trigger an immune response very effectively. Certain antiviral therapies, while expensive, are somewhat effective in treating hepatitis C, but there is no vaccine currently available to prevent hepatitis C. ChronVac-C(R) is designed to be a therapeutic DNA vaccine that can stimulate the body's immune system. Animal experiments have demonstrated that ChronVac-C vaccination activated B-cells and T-cells (the latter being regarded as the most significant to clearing the chronic infection relating to hepatitis C) that killed cells producing HCV protein. In humans, the ChronVac-C DNA plasmid will be injected into muscle tissue, where vaccinations are usually given, and taken up by muscle cells with the assistance of Inovio's electroporation-based DNA delivery system. These muscle cells would be expected to then produce predetermined proteins that may activate the body's immune system to attack all cells producing HCV proteins.

###

About Tripep AB

Tripep AB is a Swedish biotechnology research company that develops and commercializes candidate drugs based on patented and proprietary technologies. Its main focuses are research and clinical development of ChronVac-C(R), a therapeutic vaccine against hepatitis C; preclinical research focusing on the development of therapeutic and prophylactic vaccines against influenza A and HIV; and the RAS(R) technology platform.

More information is available at http://www.tripep.se.

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing its proprietary Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is designed for local treatment of solid tumors, with selective killing of cancer cells while preserving surrounding healthy tissue. Inovio is moving its lead product, the MedPulser®, through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, Tripep, University of Southampton, H. Lee Moffitt Cancer Center, U.S. Army, Innogenetics and Pharmexa, with six gene-based therapies and DNA vaccines in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation and DNA vaccination, with the industry's most extensive patent portfolio covering in vivo electroporation.

More information is available at http://www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2005, our Form 10-Q for the nine months ended September 30, 2006, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

For further information please go to:
More information is available at Inovio Biomedical Corporation. And
Tripep AB.
 
 
 
Google
Web www.iconocast.com